[Form 4/A] PLUS THERAPEUTICS, INC. Amended Insider Trading Activity

Rhea-AI Filing Summary

PLUS THERAPEUTICS, INC. (PSTV) disclosure shows an amendment to an insider Form 4 for Andrew Sims, the company's Chief Financial Officer, correcting previously reported vesting terms. On 08/13/2025 Mr. Sims was awarded 1,379,636 stock options with an exercise price of $0.5744 and 459,878 restricted stock units (RSUs). The options vest over four years in equal monthly 1/48th installments and expire 08/12/2035. The amended RSU disclosure clarifies they vest over twelve quarters in substantially equal 1/12th increments beginning with the quarter ended 09/30/2025 and convert one-for-one into common shares upon vesting. The filing is signed by Mr. Sims on 10/03/2025.

Positive

• Grant clarity: Amendment clarifies RSU vesting to 12 quarters starting 09/30/2025
• Long-term alignment: Options vest over 4 years, aligning CFO incentives with multi-year performance

Negative

• Potential dilution: 1,379,636 options and 459,878 RSUs could increase outstanding shares if fully vested and exercised
• Concentration of equity: Large single-officer grants may materially affect share count depending on company size

Insights

Corporate Governance Analyst

Amendment clarifies executive compensation vesting schedule; no cash transaction disclosed.

The filing corrects the RSU vesting cadence for CFO Andrew Sims, specifying quarterly vesting over 12 quarters beginning 09/30/2025. This provides clearer timelines for when equity may convert to common shares and become freely tradable.

Because the report shows grants (options and RSUs) rather than sales, the immediate dilution impact is prospective and tied to vesting schedules and exercise activity; the options total 1,379,636 and RSUs total 459,878.

Compensation & Dilution Specialist

Large option and RSU grants create potential future dilution if fully vested and exercised.

The option award of 1,379,636 shares and RSUs of 459,878 represent specific share counts that will add to outstanding shares only as they vest and, for options, if exercised at $0.5744. The options vest over four years and expire 08/12/2035, while RSUs vest over 12 quarters.

This establishes explicit timelines for share issuance; investors can use these dates to model potential dilution and timing of insider-aligned incentives.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Sims Andrew John Hugh MacIntyre

(Last) (First) (Middle)

C/O PLUS THERAPEUTICS INC.

4200 MARATHON BOULEVARD, SUITE 200

(Street)

AUSTIN TX 78756

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PLUS THERAPEUTICS, INC. [ PSTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
08/15/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.5744	08/13/2025		A		1,379,636		(1)	08/12/2035	Common Stock	1,379,636	$0.00	1,379,636	D
Restricted Stock Units	(2)	08/13/2025		A		459,878		(2)	(2)	Common Stock	459,878	$0.00	459,878	D

Explanation of Responses:

1. The options vest over four years in equal 1/48th increments on each monthly anniversary of the issuance.

2. This amendment is being filed to correct a Form 4 filed on August 15, 2025, which inadvertently disclosed the incorrect vesting terms of the Restricted Stock Units ("RSUs"). The RSUs awarded on August 13, 2025 vest over twelve quarters, vesting in substantially equal 1/12th increments beginning with the quarter ended September 30, 2025. The RSUs convert into shares of Common Stock upon vesting on a one for one basis.

	/s/ Andrew Sims	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Andrew Sims disclose on the amended Form 4 for PSTV?

The amendment reports awards of 1,379,636 stock options at $0.5744 and 459,878 RSUs granted on 08/13/2025, and corrects the RSU vesting schedule.

When do the RSUs granted to the CFO vest?

The RSUs vest in substantially equal 1/12th increments over 12 quarters, beginning with the quarter ended 09/30/2025.

What is the exercise period for the stock options reported?

The options vest monthly over four years in 1/48th increments and expire on 08/12/2035.

Does the Form 4/A show any insider sales?

No. The filing reports awards (acquisitions) of options and RSUs; it does not disclose any sales of shares by the reporting person.

When was the amendment signed?

The amended Form 4 was signed by Andrew Sims on 10/03/2025.